What Advancis does

Advancis operates a pharmaceutical-focused corporate presence anchored at advancispharma.com, with a multi-entity international structure consisting of Advancis International and Advancis Portugal. The homepage exposes a location and language chooser (Portuguese and English), and the only first-party identifiers available are the phrased logo asset, the brand name "Advancis," and a dedicated pharma-themed WordPress front end. No products, services, therapeutic areas, manufacturing capabilities, certifications, pipeline disclosures, partnerships, customer references, headcount, or financial figures are present in the source data.

The business model cannot be characterized from the supplied evidence. The input contains no pricing information, no disclosed customers, no channel structure, no marketing spend, and no segment definition. Ownership status is also undetermined: no parent company, subsidiaries, investors, or leadership team are disclosed, and the company type is not explicitly stated in the source.

Material data gaps include: revenue and ARR, product portfolio, regulatory and compliance posture (e.g., EMA/INFARMED authorizations, GMP), headcount, funding history, management team, M&A activity, customer concentration, pricing, and AI or technology capabilities. Any PE/VC/M&A assessment of Advancis based on this input alone would need to source these dimensions independently before valuation, competitive positioning, or risk analysis can be performed with confidence.

Name

Advancis

Website

https://advancispharma.com

Company type

Private

Founded year

1985

Operating status

Operating

Headcount range

101–250 employees

Short description

Advancis is a privately observed pharmaceutical-branded organization operating across at least two entities (Advancis International and Advancis Portugal), serving Portuguese-speaking and broader European markets via a bilingual corporate website; no products, financials, or customer base are disclosed in the source.

Ownership category

akta.pro rank

Headquarters

HQ city

São Domingos De Rana

HQ country

Portugal

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Supply Chain

Core offering

Advancis operates as a pharmaceutical company based on its advancispharma.com domain. Specific products, therapeutic areas, or service offerings are not described in the available homepage content, which consists primarily of site navigation and language/location selectors.

Differentiator

Problem solved

Functional benefit

Products and services

• Pharmaceutical products (unspecified) Advancis' homepage references its pharmaceutical business but does not list any specific products, therapeutic areas, or branded medicines. No distinct, named sellable offerings are evidenced.

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves2 records

Expansion highlights3 records

Direct peers

• Medinfar: Portuguese pharmaceutical company with branded consumer health and pharma products distributed in Iberia and selected international markets. Similar mid-size European pharma profile.
• Bial - Portela & Cª, S.A. Portuguese-headquartered pharmaceutical manufacturer with an established international footprint. Directly comparable to Advancis in domicile, scale profile, and European pharma business model.
• KRKA: Slovenian-headquartered generic pharmaceutical manufacturer with extensive European and CIS footprint. Comparable on scale, generic-led model, and export-oriented strategy from a smaller European home market.
• Stada Arzneimittel: European-focused generics and consumer health company. Closely comparable mid-cap European pharma with similar geographic emphasis and generic-plus-branded model.
• Tecnimede Group: Portuguese pharma group operating in branded generics and out-licensing across multiple European and emerging markets. Highly comparable on geography, business model, and therapeutic breadth.

Broad incumbents

• Almirall: Spanish-headquartered European dermatology and specialty pharma company. Relevant as a Southern-European pharma peer with similar cross-border commercial ambitions and Iberian roots.
• Viatris: Global off-patent branded and generic medicines company (formed via Mylan-Upjohn combination). Sets the scale benchmark for off-patent pharma and shapes European generic pricing dynamics.
• Teva Pharmaceutical Industries: Global leader in generics and specialty medicines. Provides the broader competitive backdrop against which mid-size European generic and branded-generic players like Advancis must compete on pricing and portfolio breadth.
• Recordati: European specialty and generic pharmaceutical group with strong presence in Iberia. Comparable in European mid-cap pharma positioning and primary-care/rare-disease balance.

Others

• Sandoz (Novartis): Global generics and biosimilars business. Defines the upper-bound competitive pressure on European mid-size generic manufacturers across pricing, supply reliability, and regulatory depth.

Market position

Strengths2 records

Weaknesses2 records

Competitive moat2 records

Key risks3 records

Key highlights2 records

Customer concentration

• Facebookfacebook.com/advancispharmainternational
• LinkedInlinkedin.com/company/advancispharmainternational

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Advancis